- Previous Close
486.30 - Open
488.00 - Bid --
- Ask --
- Day's Range
484.70 - 493.60 - 52 Week Range
271.00 - 493.60 - Volume
69,012 - Avg. Volume
64,406 - Market Cap (intraday)
29.157B - Beta (5Y Monthly) 0.31
- PE Ratio (TTM)
-- - EPS (TTM)
-3.17 - Earnings Date Oct 31, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
473.99
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
www.argenx.comRecent News: ARGX.BR
View MorePerformance Overview: ARGX.BR
Trailing total returns as of 9/6/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARGX.BR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARGX.BR
View MoreValuation Measures
Market Cap
29.16B
Enterprise Value
26.39B
Trailing P/E
--
Forward P/E
106.38
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
19.80
Price/Book (mrq)
7.60
Enterprise Value/Revenue
18.16
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-12.31%
Return on Assets (ttm)
-5.51%
Return on Equity (ttm)
-5.74%
Revenue (ttm)
1.66B
Net Income Avi to Common (ttm)
-204.34M
Diluted EPS (ttm)
-3.17
Balance Sheet and Cash Flow
Total Cash (mrq)
3.1B
Total Debt/Equity (mrq)
0.80%
Levered Free Cash Flow (ttm)
-223.88M